– GERMANY, Dreieich – Biotest AG (FRA: BIO), today announced that the Supervisory Board in its today meeting, appointed Dr. Michael Ramroth as Chairman of the Board of Management effective May 1st, 2019. He will take over the role as CEO from Dr. Bernhard Ehmer whose appointment will then end after four and a half years for reasons of age.
Dr. Ramroth has been a member of the Board of Management of Biotest AG since 2004. He joined Biotest from a position as Chairman for Business Development at Metallgesellschaft Technologies AG. From 1999 he had worked as CFO for the same company. From 1997 to 1999 he was CEO of CeramTec AG and from 1990 to 1997 Director of Business Development at Metallgesellschaft AG. Dr. Ramroth is a lawyer and has a doctorate in economics.
Besides Dr. Michael Ramroth as CEO, Dr. Georg Floss will continue to be a member of the Board of Management of Biotest as COO. Dr. Floss will assume additional responsibilities starting May 1st, 2019.
Biotest AG is very pleased that Dr. Bernhard Ehmer will be available for consulting services in strategic projects.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors, and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Besides, Biotest develops monoclonal antibodies in specific cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
For more information: https://www.biotest.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.